Consun Pharmaceutical Group Limited (HKG:1681)

Market Cap	12.71B +58.7%
Revenue (ttm)	3.80B +15.2%
Net Income	1.20B +18.4%
EPS	1.40 +15.6%
Shares Out	841.55M
PE Ratio	10.77
Forward PE	8.90
Dividend	0.80 (5.18%)
Ex-Dividend Date	Jun 9, 2026

Volume	1,043,000
Average Volume	1,413,302
Open	15.50
Previous Close	15.43
Day's Range	15.00 - 15.50
52-Week Range	9.34 - 19.49
Beta	0.54
RSI	38.45
Earnings Date	Aug 20, 2026

About HKG:1681

Consun Pharmaceutical Group Limited researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China. It operates in two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granule to treat chronic kidney diseases; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function ass...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1997
• Employees: 3,073
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1681

Financial Performance

In 2025, HKG:1681's revenue was 3.42 billion, an increase of 15.17% compared to the previous year's 2.97 billion. Earnings were 1.08 billion, an increase of 18.41%.

Financial numbers in CNY